Spots Global Cancer Trial Database for A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
Official Title: A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)
Study ID: NCT03264547
Conditions
Study Description
Brief Summary: To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no medical history of chemotherapy except ado-trastuzumab emtansine
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
National Hospital Organization Osaka National Hospital, Ōsaka, Osaka, Japan
Contact Details
Name: Toshinari Tamashita, MD, PhD
Affiliation: Kanagawa Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Norikazu Masuda, MD, PhD
Affiliation: NHO Osaka National Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Shigehira Saji, MD, PhD
Affiliation: Fukushima Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
